Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Updates - Valiant Bio-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company announced that the first patient has successfully received treatment in the Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] Group 2: Clinical Research - The trial aims to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple-negative breast cancer [1]

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

格隆汇2月13日丨三生国健(688336.SH)公布，公司的抗IL-17A人源化单克隆抗体安沐奇塔单抗注射液 （商品名：益赛拓®，以下简称"安沐奇塔单抗"）的新药上市申请已经获得国家药品监督管理局批准， 用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病成人患者。 安沐奇塔单抗具有皮损清除能力强且起效快、免疫原性低、安全性和耐受性良好、给药便捷性高等多方 面的核心优势，已得到了多个大样本量临床研究数据的充分验证。 ...

Core Viewpoint - The company, Olin Bio (688319.SH), is progressing towards a dual listing in Hong Kong, which could enhance its capital structure and international presence, while facing regulatory uncertainties regarding the approval process [1][2]. Stock Performance - As of February 13, 2026, Olin Bio's A-share price closed at 27.13 yuan, up 4.59%, with a trading volume of 255 million yuan and a turnover rate of 2.29% [1]. Strategic Advancement - The company aims to leverage the Hong Kong listing to accelerate its "bring in" (international patents and talent) and "go out" (global sales and technology transfer) strategies, focusing on differentiated areas such as superbug vaccines and adult vaccines [2]. - In November 2025, the company received a "satisfactory compliance" rating from the Philippines FDA, facilitating entry into the Southeast Asian market, and established a vaccine production partnership with Griffith University in Australia [2]. Project Development - The proceeds from the Hong Kong listing will be allocated to the clinical development of the rHPV (Helicobacter pylori) vaccine, expansion of the III phase clinical trials for the golden staph vaccine, and upgrades to production facilities [3]. - The restructured golden staph vaccine has completed enrollment of 6,000 cases for the III phase clinical trial, with complete data expected in the first half of 2026; the quadrivalent influenza virus split vaccine (MDCK cells) commenced its III phase clinical trial in October 2025 [3]. Future Development - The Hong Kong listing is anticipated to attract international investors, broadening financing channels, which is particularly beneficial for the long-term investment required in innovative vaccine research and development [4]. - A dual listing is expected to enhance the company's international visibility, promoting business development collaborations and expansion into overseas markets [5].

Group 1 - The article emphasizes the importance of financial support in overcoming the industrialization bottlenecks of "bottleneck" technologies in the biotechnology sector, aligning with the national innovation-driven development strategy and the demand for high-quality development in the future biotechnology industry [1] - Beijing Dingchi Biotechnology Co., Ltd. is highlighted as a leading enterprise in the upstream core consumables and innovative animal health sectors of domestic biopharmaceuticals, focusing on serum-free cell culture systems and key technologies for genetically engineered vaccines [1] - The urgent need for self-controlled key raw materials in biopharmaceuticals and the expanding market scale of innovative animal health indicate significant growth potential for the industry amid the wave of domestic substitution [1] Group 2 - China CITIC Bank Beijing Branch is noted for its commitment to the national innovation-driven development strategy, breaking away from traditional credit thinking that emphasizes collateral and past performance [2] - The bank has introduced a technology achievement transformation loan product, creating a specialized evaluation system focused on technological barriers, R&D strength, and market potential, aimed at providing precise "patient capital" for new productive forces [2] - CITIC Bank has provided 10 million yuan in critical financing support to Dingchi Biotechnology, facilitating financial services to earlier-stage, smaller, and more robust biotechnology enterprises, thereby supporting the domestic production of core biopharmaceutical consumables and the upgrade of the innovative animal health industry [2]

Group 1 - The core point of the article is that Hite Bio (300683) plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, effectively achieving full control [1] - This acquisition is a follow-up to a share purchase agreement signed in 2014 and aims to integrate the innovative drug research and development platform, paving the way for the commercialization of the core drug CPT (recombinant structural human tumor necrosis factor-related apoptosis-inducing ligand) [1] - The share acquisition process has taken over ten years, and this transaction marks the final stage of integration [1] Group 2 - In the past week (February 7 to 13, 2026), Hite Bio's stock price has shown a volatile downward trend, peaking at 36.03 yuan on February 10, with a single-day increase of 3.17%, but subsequently retracing to a closing price of 32.22 yuan on February 13, resulting in a cumulative decline of 3.13% over five days [2] - On February 10, the turnover rate reached 9.89%, with a trading volume of 419 million yuan, indicating active short-term trading; however, on February 12, there was a net outflow of 14.9611 million yuan from main funds, accounting for 9.75% of the total trading volume [2] - The technical analysis indicates increased volatility in the stock price, with the 20-day Bollinger Bands showing a resistance level at 35.12 yuan and a support level at 27.72 yuan [2] Group 3 - Institutional attention on Hite Bio is relatively low, with the latest sentiment being neutral; one institution predicts a net profit of 77 million yuan for 2025, representing a year-on-year increase of 283.33%, and a forecast of 339 million yuan for 2026, reflecting a year-on-year growth of 340.26%, primarily due to expectations regarding the commercialization potential of the innovative drug CPT [3] - Currently, 100% of institutional ratings are neutral, with no clear target price guidance provided [3]

Group 1 - The core viewpoint of the article highlights the significant rise in Chinese pharmaceutical stocks, with many companies experiencing substantial stock price increases, referred to as "X-fold stocks" [1] - The article discusses the emergence of several "three-fold," "four-fold," and even "ten-fold" stocks in the Hong Kong market, driven by various factors including overseas product licensing and market recovery [1] Group 2 - Beihai Kangcheng, once known as the "first stock in rare diseases," has struggled financially but saw a turnaround after a share subscription agreement with Baiyang Pharmaceutical, leading to a significant increase in its stock price [5][6][7] - Sanleaf Biotech, which went public in 2021, has faced challenges in the vaccine market, resulting in continuous losses, but is focusing on developing RSV vaccines as a potential growth area [8][9] - Yaojie Ankang experienced a dramatic stock price increase shortly after its IPO, driven by speculative trading, but has since seen a decline in its market value [9][10] - Hecui Pharmaceutical has established itself as a leader in business development (BD) transactions, achieving significant revenue through collaborations with multinational pharmaceutical companies [10][11][12] - Xuan Bamboo Biotech benefited from a new subscription mechanism in Hong Kong, achieving an oversubscription of nearly 5000 times, and has a solid pipeline of products [13][14] - Deqi Pharmaceutical has regained institutional recognition and is expected to see a valuation rebound due to promising clinical data from its drug candidates [15][16] - Jako Pharmaceutical successfully developed a KRAS G12C drug, marking a significant achievement in targeting previously deemed "undruggable" targets [17] - Rongchang Biotech anticipates a return to profitability in 2025, driven by strong sales growth of its core products [18][19][20] - Paige Biopharma is focusing on the GLP-1 market, with several drugs in development, capitalizing on the growing demand for weight loss medications [21] - Baiaosaitu, a CRO, has differentiated itself in the market by integrating AI into its drug development processes, showcasing a unique growth trajectory [22][23][24]

Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building a commercial production base for advanced CAR-T cell therapy products in Shanghai, aligning with its commercialization efforts for multiple CAR-T therapies [1] Group 1: Investment and Strategic Partnership - The investment will be made through the company's wholly-owned subsidiary, Shanghai Kaixing Diagnostic Technology Co., Ltd., in collaboration with Shanghai Jinguang Enterprise Development Co., Ltd. [1] - The total investment amount is capped at RMB 370 million, indicating a significant commitment to expanding production capabilities [1] Group 2: Product Development and Commercialization - The new production base will support the commercialization of several CAR-T cell therapy products, including the already launched product, Sai Kaize®, and the product under new drug application, CT041 (proposed brand name "Kailimei") [1] - The initiative aims to lay the groundwork for future mass production of various universal CAR-T cell therapy products, such as CT0596 and CT1190B [1] Group 3: Operational and Financial Strategy - The transaction allows the company to avoid large capital expenditures initially, preserving cash flow for core research and market expansion [1] - A buyback mechanism is in place to ensure the company can gain complete control of the assets after long-term operations, maintaining production stability and enhancing asset layout flexibility [1]

Group 1 - Core viewpoint: Morgan Stanley's report indicates that WuXi Biologics (02269) has exceeded market consensus and Morgan Stanley's expectations for its 2025 performance, leading to an increase in target price from HKD 37 to HKD 51 and maintaining an "Overweight" rating [1] - Company expects full-year revenue of RMB 21.8 billion, a year-on-year increase of 16.7%, aligning with market consensus and Morgan Stanley's forecast [1] - Net profit is projected to reach RMB 4.9 billion, exceeding market consensus and Morgan Stanley's estimates by approximately 11% and 17% respectively [1] Group 2 - Morgan Stanley has raised its sales forecasts for 2025 to 2027 by 2% to 5%, and for 2028 and beyond by 6% to 9%, due to improved expectations for new order acquisition momentum [2] - The firm now predicts sales growth of 17.3% and 18.0% for 2026 and 2027 respectively [2] - Due to better-than-expected gross margin expansion, Morgan Stanley has adjusted its gross margin assumptions upward by 2 to 3 percentage points, forecasting gross margins of 46.0%, 46.2%, and 46.5% for 2025, 2026, and 2027 respectively [2]

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]